Stoke Therapeutics (STOK) Accounts Payables (2022 - 2025)
Historic Accounts Payables for Stoke Therapeutics (STOK) over the last 4 years, with Q3 2025 value amounting to $5.9 million.
- Stoke Therapeutics' Accounts Payables rose 13625.75% to $5.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.9 million, marking a year-over-year increase of 13625.75%. This contributed to the annual value of $2.5 million for FY2024, which is 4737.46% up from last year.
- Latest data reveals that Stoke Therapeutics reported Accounts Payables of $5.9 million as of Q3 2025, which was up 13625.75% from $4.3 million recorded in Q2 2025.
- In the past 5 years, Stoke Therapeutics' Accounts Payables ranged from a high of $5.9 million in Q3 2025 and a low of $766000.0 during Q4 2022
- Over the past 4 years, Stoke Therapeutics' median Accounts Payables value was $2.5 million (recorded in 2024), while the average stood at $2.9 million.
- In the last 5 years, Stoke Therapeutics' Accounts Payables crashed by 5680.18% in 2023 and then skyrocketed by 15353.47% in 2024.
- Over the past 4 years, Stoke Therapeutics' Accounts Payables (Quarter) stood at $766000.0 in 2022, then surged by 121.28% to $1.7 million in 2023, then surged by 47.37% to $2.5 million in 2024, then skyrocketed by 135.03% to $5.9 million in 2025.
- Its Accounts Payables was $5.9 million in Q3 2025, compared to $4.3 million in Q2 2025 and $2.2 million in Q1 2025.